Express Pharma

Dr. Reddy’s receives EIR for FTO-3 Bachupally plant

0 546

During the inspection, the facility received 10 observations

Dr Reddy’s Laboratories notified stock exchanges that its formulations manufacturing facility (FTO-3) in Bachupally, Hyderabad, has been issued an Establishment Inspection Report (EIR) by the US Food and Drug Administration following an inspection conducted in October 2023.

According to Dr Reddy’s, the USFDA has categorised the inspection outcome as Voluntary Action Indicated (VAI). During the inspection, the facility received 10 observations.

- Advertisement -

Leave A Reply

Your email address will not be published.